Trials / Unknown
UnknownNCT05947097
A Study to Evaluate the Pharmacokinetics of HSK21542 in Subjects With Renal Impairment
An Open-label, Single-dose Study to Assess the Pharmacokinetics of HSK21542 Injection in Subjects With Varying Degrees of Renal Impairment Compared to the Control Subjects With Normal Renal Function
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of HSK21542 in subjects with mild, moderate and severe renal impairment compared to the matched control subjects with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSK21542 Injection | 1ug/kg bolus for 2min±5s |
Timeline
- Start date
- 2023-04-24
- Primary completion
- 2023-07-30
- Completion
- 2023-12-30
- First posted
- 2023-07-17
- Last updated
- 2023-07-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05947097. Inclusion in this directory is not an endorsement.